BofA downgraded Agilon Health (AGL) to Underperform from Buy with a price target of $3, down from $10.50, citing a deteriorating environment for Medicare Advantage companies and “a slew of
BofA downgraded Agilon Health (AGL) to Underperform from Buy with a price target of $3, down from $10.50, citing a deteriorating environment for Medicare Advantage companies and “a slew of
מחיר המניה של Humana ירד ב-17.6%, כלומר הוא דעך ב-49.06 דולר, וכעת עומד על 230.39 דולר.
Humana is down -17.6%, or -$49.06 to $230.39. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by
After Humana released an 8-K this morning indicating that preliminary Medicare Advantage Star Ratings data available on CMS Plan Finder as of October 1 shows only 25% of the company’s
Humana confirmed a significant decline in its quality ratings based on preliminary stars data released in CMS Plan Finder on Tuesday, which RBC Capital tells investors in a research note